Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) and Kineta (NASDAQ:KA – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Insider & Institutional Ownership 89.8% of Jazz Pharmaceuticals shares are held […]
Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023
. | May 11, 2023
HC Wainwright restated their buy rating on shares of Kineta (NASDAQ:KA – Get Rating) in a research note released on Monday, The Fly reports. HC Wainwright also issued estimates for Kineta’s Q1 2023 earnings at ($0.72) EPS, Q2 2023 earnings at ($0.68) EPS, Q3 2023 earnings at ($0.46) EPS, Q4 2023 earnings at ($0.37) EPS, […]
Kineta (NASDAQ:KA – Get Rating)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Monday, The Fly reports. Kineta Trading Up 1.2 % Shares of NASDAQ KA opened at $4.11 on Monday. Kineta has a twelve month low of $2.87 and a twelve month high of $15.54. The company has […]
Monday May 1, 2023 Trading Desk: (312) 236-8907 TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 9:45ET S&P Global US Manufacturing PMI; 10:00ET Construction Spending MoM, ISM Manufacturing TODAY’S HIGHLIGHTS: JPMORGAN TO MAKE PAYMENT OF $10.6B TO FDIC ON FIRST REPUBLIC Global markets were muted as trading was closed